Approved Research This page provides a searchable list of all research protocols that have been reviewed and approved by the Uganda National Council for Science and Technology(UNCST).
Search By Approval Date:
Clear Filter Total: 6,466
Name Title Nationality Approval Date Expiry Date Field of Science/Classification Trial Type Research Type  
Victoria Nankabirwa
ID: UNCST-2021-R011871
 Effectiveness of mobile money payments to vaccination campaign health care workers on polio vaccination campaign coverage and quality: a cluster randomized controlled trial
REFNo: HS1932ES

Primary Objectives:
1) To compare vaccination coverage in areas where campaign health care workers are paid using mobile money versus in cash.
2) To compare the motivation, satisfaction and performance of vaccination health care workers in areas where they are paid using mobile money versus in cash

Secondary objectives:
1) To compare vaccination campaign quality in areas where health care workers are paid using mobile money versus in cash
2) To estimate the incremental cost of the intervention.

 Uganda 2021-12-20 2024-12-20 Medical and Health Sciences Non-Clinical Trial Non-degree Award
SSEMBATYA RENNY
ID:
COVID/COPE Study: An Interdisciplinary Empirical Approach to Understanding Unequal Economic and Health Consequences of COVID-19 Measures among Pregnant Women in Uganda
REFNo: SS936ES

Objective 1: To analyze the effects of Covid-19 measures among pregnant women in Uganda of varying size, socio-economic, health and poverty indexes.
Objective 2: To assess the proportion of pregnant women with symptoms, rates of social interactions; financial and non-financial costs; how pregnant women have recently responded to the Covid-19 measures, especially in relation to their personal circumstances and expectations.
Objective 3: To provide recommendations how to improve access to care for these vulnerable populations and prevent unnecessary, delayed care while safeguarding public health concerns.

Uganda 2021-12-17 2024-12-17 Social Science and Humanities Non-Clinical Trial Non-degree Award
Obondo Sande James
ID: UNCST-2019-R000241
 Capacity Building towards Primary Immunodeficiency Disorders Research, Diagnosis, and Clinical Management in Uganda
REFNo: HS1867ES

3. To strengthen local laboratory screening and research capacity in the management of PIDs. ,2. To increase knowledge on PIDs among clinicians, pediatricians, laboratory technologists, immunologists through training focused on detection of potential PIDs cases. ,1. To map and create profiles of the current PIDs knowledge and diagnostic capacity in Uganda,To evaluate clinical and laboratory diagnostic knowledge about PIDs, and undertake PIDs-focused training in Uganda,
 Uganda 2021-12-17 2024-12-17 Medical and Health Sciences Non-Clinical Trial Non-degree Award
Claudia Ringler
ID:
Endline Evaluation for Reaching Smallholder Women with Information Services and Resilience Strategies to Respond to Climate Change
REFNo: SS1127ES

3) At the endline (The subject of this application, to be undertaken in January of 2022), the study will establish the impact of the strategies used to disseminate the climate-smart technologies and approaches and whether these translate into closing gendered yield gaps, enhanced equity and inclusion.
 Germany 2021-12-17 2024-12-17 Social Science and Humanities Non-Clinical Trial Non-degree Award
Victoria Ndyanabangi
ID: UNCST-2021-R012645
 Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum,DAIDS Study ID #38609, IND #146262
REFNo: HS1023ES

Primary Objectives
Component 1:
• To describe the PK parameters during pregnancy of selected ARV drugs administered to WLHIV who are not receiving TB drugs, and to compare these parameters to (a) historical PK data from non-pregnant women and (b) each participant’s own postpartum PK data.
Component 2:
• To describe the kinetics of (a) placental and breast milk transfer of CAB LA from mother to fetus/infant and (b) infant elimination of CAB LA acquired across the placenta after maternal dosing during pregnancy.
Component 3:
• To describe the PK parameters during pregnancy and postpartum of selected ARV drugs and first-line TB treatment drugs co-administered to WLHIV.
Component 4:
• To describe the PK parameters during pregnancy and postpartum of second-line TB treatment drugs administered to WLHIV and HIV-uninfected women.
Component 5:
• To describe the kinetics of drug transfer of selected ARVs from mother to infant via breast milk.
Secondary Objectives
All Components:
• To describe maternal and infant safety and clinical outcomes.
Components 1, 3 and 4:
• To compare drug concentrations in plasma from cord blood with concentrations in maternal plasma at delivery for selected ARV and/or TB treatment drugs.
• To describe the neonatal elimination of selected ARV and/or TB treatment drugs acquired across the placenta after maternal dosing during pregnancy.
Components 3 and 4:
• To describe the kinetics of drug transfer of selected ARVs and/or TB treatment drugs from mother to infant via breast milk
Component 4:
• To describe the PK parameters of selected ARVs when co-administered with selected second-line TB treatment drugs to WLHIV during pregnancy and postpartum.
Other Objectives
• To assess plasma protein binding of highly bound ARVs and/or TB treatment drugs during pregnancy and postpartum.
• To explore genetic sources for variability in drug exposure in pregnant and postpartum women and their infants for selected ARV and/or TB treatment drugs.

 Uganda 2021-12-16 2024-12-16 Medical and Health Sciences Non-degree Award
View Sort By:

"A prosperous Science and Technology Led Ugandan Society."

NRIMS